Serina Therapeutics secures $5 million to fund Parkinson’s trial

Serina Therapeutics, a clinical-stage biotechnology company, has drawn the first $5 million tranche of a potential $20 million financing agreement to advance its registrational trial of SER-252 for advanced Parkinson’s disease, according to the company. Subsequent funding tranches are linked to spec…